MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Author:

Hu Shimin1,Xu-Monette Zijun Y.1,Tzankov Alexander2,Green Tina3,Wu Lin4,Balasubramanyam Aarthi4,Liu Wei-min4,Visco Carlo5,Li Yong6,Miranda Roberto N.1,Montes-Moreno Santiago7,Dybkaer Karen8,Chiu April9,Orazi Attilio10,Zu Youli11,Bhagat Govind12,Richards Kristy L.13,Hsi Eric D.14,Choi William W. L.15,Zhao Xiaoying16,van Krieken J. Han17,Huang Qin18,Huh Jooryung19,Ai Weiyun20,Ponzoni Maurilio21,Ferreri Andrés J. M.21,Zhou Fan22,Slack Graham W.23,Gascoyne Randy D.23,Tu Meifeng24,Variakojis Daina25,Chen Weina26,Go Ronald S.27,Piris Miguel A.7,Møller Michael B.3,Medeiros L. Jeffrey1,Young Ken H.1

Affiliation:

1. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;

2. University Hospital, Basel, Switzerland;

3. Odense University Hospital, Odense, Denmark;

4. Roche Molecular Systems, Pleasanton, CA;

5. San Bortolo Hospital, Vicenza, Italy;

6. University of Louisville, Louisville, KY;

7. Hospital Universitario Marques de Valdecilla, Santander, Spain;

8. Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark;

9. Memorial Sloan-Kettering Cancer Center, New York, NY;

10. Weill Medical College of Cornell University, New York, NY;

11. The Methodist Hospital, Houston, TX;

12. Columbia University Medical Center and New York Presbyterian Hospital, New York, NY;

13. University of North Carolina School of Medicine, Chapel Hill, NC;

14. Cleveland Clinic, Cleveland, OH;

15. Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China;

16. Zhejiang University School of Medicine, Second University Hospital, Hangzhou, China;

17. Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands;

18. City of Hope National Medical Center, Duarte, CA;

19. Asan Medical Center, College of Medicine, Ulsan University, Seoul, Korea;

20. School of Medicine, University of California San Francisco, San Francisco, CA;

21. San Raffaele H. Scientific Institute, Milan, Italy;

22. Southwest Washington Medical Center, Vancouver, WA;

23. BC Cancer Agency and BC Cancer Research Centre, Vancouver, British Columbia, Canada;

24. Peking University School of Oncology, Beijing Cancer Hospital, Beijing, China;

25. Feinberg School of Medicine, Northwestern University, Chicago, IL;

26. Ameripath/Quest Diagnostics, Dallas, TX; and

27. Gundersen Lutheran Health System, La Crosse, WI

Abstract

Key Points DLBCL patients with MYC/BCL2 coexpression demonstrate inferior prognosis and high-risk gene expression signatures.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3